ERBB2 and breast carcinoma: Although the aptamer generated in this study demonstrates remarkable selectivity for HER2 receptors on the surface of HER2-positive breast cancer cells, further analyses are necessary to improve the hallmarks of the DNA aptamer HMAP7 through chemical modifications (Ni et al., 2017; Camorani et al., 2020) to increase its nuclease resistance, and to assess its efficacy in vivo.